Soluble tumor necrosis factor receptors and ca 125 in serum as markers for epithelial ovarian cancer

Tumor Biology

Volumn 17, Issue 2, 1996, Pages 90-96

  Onsrud, Mathias ^a   Shabana, Ayman ^a   Austgulen, Rigmor ^b  

^a TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

CA125; Ovarian neoplasms; Tumor necrosis factor receptor

Indexed keywords

CA 125 ANTIGEN; TUMOR MARKER; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PRIORITY JOURNAL;

EID: 0030009286     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1159/000217971     Document Type: Article

References (27)

1. Beutler B, Cerami A: The biology of caehectin/TNF: A primary mediator of the host response. Annu Rev Immunol 1989;7:625-655.
2. Fiers W: Tumor necrosis factor: Characterization at the molecular, cellular and in vivo level. FEBS Lett 1991:285:199-212.
3. Balkwiil FR, Ward BG, Moodie E, Fiers W: Therapeutic potential of tumor necrosis factor-n and y-inter-feron in experimental human ovarian cancer. Cancer Res 1987:47: 4755-4758.
4. Malik STA, Griffin DB, Fiers W, Balkwiil FR: Paradoxical effects of tumor necrosis factor in experimental ovarian cancer. Int J Cancer 1989;44:918-925.
5. Aggarwal B, Eessalu T, Hass P: Characterization of receptors for human tumour necrosis factor and their regulation by y-intcrferon. Nature 1985:318:665-667.
6. Brockhaus M, Schonfcld H, Schla-ger E, Hinziker W, Lcsslauer W, Loctscher H: Identification of two kinds of TNF receptors on human cell lines by monoclonal antibodies. Proc Natl Acad Sci USA 1990:87: 3127-3131.
7. Liabakk N, Sundan A, Waage A, Brockhaus M, Loctchcr H, Lesslauer W, Espevik T: Development of immunoassays for the detection of soluble TNF receptors. J Immunol Methods 1991:141:237-243.
8. Lanlz M, Gullberg U, Nilsson E, Olsson I: Characterization in vitro of a human tumor necrosis factor-binding protein: A soluble form of tumor necrosis factor receptor. J Clin Invest 1990;86:1336-1342.
9. Van Zee KJ, Kohno T, Fisher E, Rock CS, Moldawar LL, Lowry SF: Tumor receptor factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. Proc Natl Acad Sci USA 1993; 89:4845-4849.
10. Mohler KM, Torrance DS, Smith CA, Godwin RG, Stremler KE, Fung VP, Madani H, Widmer MB: Soluble tumor necrosis factor (TNF) receptors arc effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 1993:151:1548-1561.
11. Aderka D, Engelmann H, Hornik V, Levo Y: The possible role of tumor necrosis factor (TNF) and its natural inhibitors, the soluble TNF receptors, in autoimmune diseases. Isr J Med Sci 1992;28:126-130.
12. Aderka D, Engclmann H, Maor Y, Brakcbusch C, Wallach D: Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med 1992;175:323-329.
13. Olsson I, Gatanaga T, Bullberg U, Lantz M, Granger GA: Tumor necrosis factor (TNF) binding proteins (soluble TNF receptor forms) with possible roles in inflammation and malignancy. Eur Cytokine Netw 1993;4:169-180.
14. Aderka D, Engelmann H, Shcmer-Avni Y, Hornik V, Galil A, Sarov B, Wallach D: Variation in serum levels of the soluble TNF receptors among healthy individuals. Lymphokinc Cytokine Res 1992:11: 157-159.
15. Gatanaga T, Lentz R, Masunaka I, Tomich J, Jelfes EWB, Baird M, Granger GA: Identification of TNF-LT blocking factor(s) in the serum and ultrafiltrates of cancer patients. Lymphokinc Res 1990:9:225-229.
16. Gatanaga T, Hwang C, Kohr W, Cappuchini F. Lucci JA. Jeffes EWB. Lentz R, Tomich J, Yamamoto R, Granger GA: Purification and characterization of an inhibitor (soluble tumor necrosis factor receptor) for the tumor necrosis factor and lymphotoxin from the serum ultrafiltrates of human cancer patients. Proc Natl Acad Sci USA 1990;87: 8781-8784.
17. Aderka D, Engelmann H, Hornik V, Skomick Y, Levo Y, Wallach D, Kushtai G: Increased serum levels of soluble receptors for tumour necrosis factor in cancer patients. Cancer Res 1991;51:5602-5607.
18. Grosen E, Grange G, Gatanaga M, Ininns E, Hwang C, DiSaia P, Berman N, Manetta A, Emma D, Gatanaga T: Measurement of the soluble membrane receptor for tumor necrosis factor and lymphotoxin in the sera of patients with gynecologic malignancy. Gynecol Oncol 1993: 50:68-77.
19. Bast RC, Klug TL. St John E, Jenison E, Niloff JM. Lazarus H, Berkowitz RS, Leawitt T, Griffiths CT. Parker L, Zurawski VR Jr, Knapp RC: A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983:309:883-887.
20. Vergote IB, Bormer OP, Abeier VM: Evaluation of scrum CA 125 levels in the monitoring of ovarian cancer. Am J Obstet Gynecol 1987;157:88-92.
21. Vergote IB, Abeler VM, Bormer OP, Stigbrantl T, Tropé C, Nuslad K: CA 125 and placental alkaline phosphatase as serum tumor markers in epithelial ovarian carcinoma. Tumor Biol 1992:13:168-174.
22. Malkasian G, Knapp RC, Lavin P, Zurawski V, Podratz K, Stanhope C, Mortel R, Berek J, Bast R, Ritts R: Preoperative evaluation of serum CA 125 levels in premenopausal patients with pelvic masses: Discrimination of benign from malignant disease. Am J Obstet Gynecol 1988; 158:341-346.
23. Patsner B, Mann W: The value of preoperative serum CA 125 levels in patients with a pelvic mass. Am J Obstet Gynecol 1988:159:873-876.
24. Vasilev S, Schlaerth J, Campeau J, Morrow C: Serum CA 125 levels in preoperativc evaluation of pelvic masses. Obstet Gynecol 1988:71: 751-756.
25. Liabakk N-B, Sundan A, Lien E, Laegrcid A, Bombara MP. Ranges G, Espcvik T: The release of soluble p55 TNF receptor from U937 cells studied by a new p55 immunoassay. J Immunol Methods 1993:163:145-154.
26. Onsrud M, Shabana A, Austgulen R: Comparison between soluble tumor necrosis factor receptors and CA 125 in peritoneal fluids as a marker for epithelial ovarian cancer. Gynecol Oncol 1995;57:183-187.
27. Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinkas JG: A risk malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol 1990:97:922-929.